Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma"

Respir Med. 2022 Jan:191:106088. doi: 10.1016/j.rmed.2020.106088. Epub 2020 Jul 9.

Authors

Affiliations

¹ Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: eric.bateman@uct.ac.za.
² Sanofi, Chilly-Mazarin, France.
³ Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
⁴ Sanofi, Bridgewater, NJ, USA.
⁵ Evidera, St-Laurent, Quebec, Canada.
⁶ Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

PMID: 35090691
DOI: 10.1016/j.rmed.2020.106088

No abstract available

Keywords: Benralizumab; Dupilumab; Indirect treatment comparison; Matching-adjusted indirect comparison; Mepolizumab; Severe eosinophilic asthma.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Biological Products* / therapeutic use
Humans

Substances

Antibodies, Monoclonal, Humanized
Biological Products
dupilumab